Eye discharge adverse event reports that record this term

Kind of term: MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From February 2004 to June 2026, FDA received 10,069 adverse event reports that record the MedDRA preferred term Eye discharge. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 962 reports in the 12 months to June 2026 and 823 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 633 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 962 (0.1%) record this term. Reports for female patients were 66.3% of the reports that record this term and 52.7% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 142 drug pages with 10 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Eye discharge name as a suspect product, in order of name
Drug	Class	Reports with this term
Acetaminophen		14
Acoltremon		44
Actemra	Interleukin-6 receptor antagonist	44
Adalimumab	Tumor necrosis factor blocker	13
Adbry	Interleukin-13 antagonist	23
Afinitor	Kinase inhibitor	10
Alaway	Histamine-1 receptor inhibitor	11
Alphagan P	alpha-Adrenergic agonist	69
Ambrisentan	Endothelin receptor antagonist	11
Amlodipine	Calcium channel blocker	12
Avastin	Vascular endothelial growth factor inhibitor	94
Ayvakit	Kinase inhibitor	25
Azasite	Macrolide antimicrobial	11
Azopt	Carbonic anhydrase inhibitor	32
Beovu		18
Besivance	Quinolone antimicrobial	15
Bevacizumab	Vascular endothelial growth factor inhibitor	72
Botox	Acetylcholine release inhibitor	38
BOTOX Cosmetic	Acetylcholine release inhibitor	41
Brimonidine tartrate	alpha-Adrenergic agonist	14
Carbamazepine	Mood stabilizer	12
Cequa	Calcineurin inhibitor immunosuppressant	14
Ciprofloxacin	Fluoroquinolone antibacterial	25
Clarithromycin	Macrolide antimicrobial	10
Clindamycin	Lincosamide antibacterial	12
Combigan	alpha-Adrenergic agonist	58
Combigan R		10
Corticotropin		14
Cosentyx	Interleukin-17A antagonist	95
Cosopt	Carbonic anhydrase inhibitor	13
Cosopt Pf	Carbonic anhydrase inhibitor	51
Cyclosporine	Calcineurin inhibitor immunosuppressant	29
Dexamethasone	Corticosteroid	13
Dilaudid	Opioid agonist	13
Docetaxel	Microtubule inhibitor	21
Doxycycline	Tetracycline-class drug	10
Dupilumab	Interleukin-4 receptor alpha antagonist	119
Dupixent	Interleukin-4 receptor alpha antagonist	1,717
Enbrel	Tumor necrosis factor blocker	215
Erlotinib	Kinase inhibitor	15
Eylea	Vascular endothelial growth factor inhibitor	93
Folic acid		14
Forteo	Parathyroid hormone analog	16
Genteal Mild		12
Genteal Moderate To Severe Gel Drops		12
Gilenya	Sphingosine 1-phosphate receptor modulator	56
Gilotrif	Kinase inhibitor	10
Gleevec	Kinase inhibitor	17
Humalog	Insulin analog	14
Human immunoglobulin g	Human immunoglobulin G	11
Humira		228
Hydromorphone hydrochloride	Opioid agonist	11
Hydroxychloroquine	Antimalarial	13
Ibrance	Kinase inhibitor	43
Ibuprofen	Nonsteroidal anti-inflammatory drug	17
Ilevro	Nonsteroidal anti-inflammatory drug	14
Imbruvica	Kinase inhibitor	23
Incivek		10
Inflectra	Tumor necrosis factor blocker	47
Infliximab	Tumor necrosis factor blocker	47
Lacrisert		13
Lamictal	Anti-epileptic agent	88
Lamotrigine	Anti-epileptic agent	36
Lastacaft	Histamine-1 receptor antagonist	41
Latanoprost	Prostaglandin analog	57
Latisse	Prostaglandin analog	183
Latisse 0 03%		33
Leflunomide	Antirheumatic agent	16
Lenalidomide	Thalidomide analog	14
Levofloxacin	Fluoroquinolone antibacterial	10
Lotemax	Corticosteroid	37
Lucentis	Vascular endothelial growth factor inhibitor	171
Lumify		24
Lumigan	Prostaglandin analog	68
Lumigan 0 01%		11
Lyrica		28
Metformin	Biguanide	11
Methotrexate	Folate analog metabolic inhibitor	57
Methotrexate sodium	Folate analog metabolic inhibitor	19
Miebo		40
Naproxen	Nonsteroidal anti-inflammatory drug	16
Omalizumab	Anti-IgE	18
Omeprazole	Proton pump inhibitor	12
Opcon-A		13
Oxervate		315
Pataday		58
Pataday Once Daily Relief	Histamine-1 receptor antagonist	157
Paxlovid		13
Pazeo		28
Pegasys	Interferon alpha	12
Pomalyst	Thalidomide analog	13
Prednisolone acetate	Corticosteroid	24
Prednisone	Corticosteroid	67
Refresh Optive	Non-Standardized chemical allergen	81
Refresh Optive Sensitive		30
Refresh Plus		17
Refresh Tears		17
Remicade	Tumor necrosis factor blocker	22
Repatha	PCSK9 inhibitor	13
Restasis	Calcineurin inhibitor immunosuppressant	582
Revlimid	Thalidomide analog	110
Rhopressa		15
Rinvoq	Janus kinase inhibitor	45
Rituxan	CD20-directed cytolytic antibody	14
Rituximab	CD20-directed cytolytic antibody	21
Rocklatan	Prostaglandin analog	11
Simbrinza	Carbonic anhydrase inhibitor	28
Skyrizi	Interleukin-23 antagonist	14
Sulfasalazine	Aminosalicylate	12
Symbicort	Corticosteroid	13
Systane		104
Systane Balance		57
Systane Geldrops		79
Systane Lubricant		13
Systane Nighttime		49
Systane Pf		57
Systane Ultra		120
Tarceva		48
Tecfidera		14
Tepezza		14
Timolol maleate	beta-Adrenergic blocker	15
Tiotropium bromide	Anticholinergic	40
Travatan Z	Prostaglandin analog	20
Tyrvaya	Cholinergic receptor agonist	11
Tysabri	Integrin receptor antagonist	15
Upneeq	Vasoconstrictor	26
Vabysmo		17
Vectibix	Epidermal growth factor receptor antagonist	11
Vedolizumab	Integrin receptor antagonist	26
Vevye	Calcineurin inhibitor immunosuppressant	60
Vigamox	Fluoroquinolone antibacterial	10
Xalatan	Prostaglandin analog	51
Xdemvy		67
Xeljanz	Janus kinase inhibitor	47
Xeloda	Nucleoside metabolic inhibitor	15
Xiidra		364
Xolair	Anti-IgE	31
Xtandi	Androgen receptor inhibitor	12
Zaditor	Histamine-1 receptor inhibitor	12
Zioptan	Prostaglandin analog	32
Zofran		13
Zometa		13

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 35 pharmacologic classes with 25 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Eye discharge name, in order of name
Class	Reports with this term
Acetylcholine release inhibitor	83
alpha-Adrenergic agonist	146
Anti-epileptic agent	136
Anti-IgE	49
Anticholinergic	56
Antimalarial	28
Atypical antipsychotic	28
beta-Adrenergic blocker	27
Calcineurin inhibitor immunosuppressant	685
Carbonic anhydrase inhibitor	132
CD20-directed cytolytic antibody	46
Corticosteroid	195
Endothelin receptor antagonist	28
Fluoroquinolone antibacterial	45
Folate analog metabolic inhibitor	78
Histamine-1 receptor antagonist	206
Histamine-1 receptor inhibitor	26
Integrin receptor antagonist	45
Interleukin-13 antagonist	32
Interleukin-17A antagonist	95
Interleukin-4 receptor alpha antagonist	1,836
Interleukin-6 receptor antagonist	44
Janus kinase inhibitor	105
Kinase inhibitor	200
Microtubule inhibitor	29
Non-Standardized chemical allergen	81
Nonsteroidal anti-inflammatory drug	79
Opioid agonist	44
Prostaglandin analog	446
Proton pump inhibitor	31
Sphingosine 1-phosphate receptor modulator	60
Thalidomide analog	137
Tumor necrosis factor blocker	371
Vascular endothelial growth factor inhibitor	440
Vasoconstrictor	26

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Eye discharge, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Eye discharge
Age	Reports	Share
Under 2	67	0.7%
2 to 11	162	1.6%
12 to 17	106	1.1%
18 to 44	1,139	11.3%
45 to 64	2,098	20.8%
65 to 74	1,225	12.2%
75 and over	1,134	11.3%
Age not given	4,138	41.1%

Sex of the patient in the reports that record Eye discharge
Sex	Reports	Share
Female	6,679	66.3%
Male	2,653	26.3%
Unknown or not given	737	7.3%

Age and sex are as the report gives them. 80.9% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Eye discharge: adverse event reports that record this term. https://reportedreactions.com/reaction/eye-discharge/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Eye discharge mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page